Bio-Path Holdings announced positive findings from its Phase 1/1b clinical trial of BP1002, a drug designed to treat refractory/relapsed...

MiNK Therapeutics will present interim Phase 2 data on AgenT-797 combined with botensilimab and balstilimab for refractory gastric cancer...

Orchestra BioMed Holdings announced positive data from a retrospective analysis of its MODERATO II study, demonstrating that atrioventricular interval...

Windtree Therapeutics announced a presentation on its drug istaroxime at the Technology and Heart Failure Therapeutics Conference. The presentation...

MediWound has launched VALUE, a pivotal Phase III trial for EscharEx®, its enzymatic treatment for venous leg ulcers (VLUs)....

Aptose Biosciences reported promising early results from its Phase 1/2 TUSCANY trial, testing a triplet therapy of tuspetinib, venetoclax,...

Aclaris Therapeutics announced the publication of research on ATI-2138, a novel dual inhibitor of ITK and JAK3, currently in...

Tasso, a leader in patient-centric blood collection, launched its next-generation dried blood spot (DBS) sample collection system. This system...

Kairos Pharma (NYSE American: KAPA) is expanding its Phase 2 clinical trial for ENV105, a drug targeting castrate-resistant prostate...

Creative Medical Technology Holdings, Inc. (CELZ) announced positive one-year follow-up data from a pilot study of CELZ-201 (AlloStem™) in...